RU2562245C2 - ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА - Google Patents

ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА Download PDF

Info

Publication number
RU2562245C2
RU2562245C2 RU2011150826/04A RU2011150826A RU2562245C2 RU 2562245 C2 RU2562245 C2 RU 2562245C2 RU 2011150826/04 A RU2011150826/04 A RU 2011150826/04A RU 2011150826 A RU2011150826 A RU 2011150826A RU 2562245 C2 RU2562245 C2 RU 2562245C2
Authority
RU
Russia
Prior art keywords
cancer
crystalline form
degrees
prd
peaks
Prior art date
Application number
RU2011150826/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011150826A (ru
Inventor
Иан Г. АРМИТЭЙДЖ
Реену ЧОПРА
Мартин Иан КУПЕР
Мэрианн ЛЭНГСТОН
Стефен П ЛЭНГСТОН
Степан Вискочил
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of RU2011150826A publication Critical patent/RU2011150826A/ru
Application granted granted Critical
Publication of RU2562245C2 publication Critical patent/RU2562245C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2011150826/04A 2009-05-14 2010-05-13 ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА RU2562245C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14
US61/216,221 2009-05-14
PCT/US2010/001415 WO2010132110A1 (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Publications (2)

Publication Number Publication Date
RU2011150826A RU2011150826A (ru) 2013-06-20
RU2562245C2 true RU2562245C2 (ru) 2015-09-10

Family

ID=42396430

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011150826/04A RU2562245C2 (ru) 2009-05-14 2010-05-13 ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА

Country Status (18)

Country Link
US (2) US9187482B2 (enExample)
EP (2) EP2430026A1 (enExample)
JP (3) JP2012526808A (enExample)
KR (2) KR20170102381A (enExample)
CN (2) CN102421780A (enExample)
AU (1) AU2010248151B2 (enExample)
BR (1) BRPI1012142A2 (enExample)
CA (1) CA2761256C (enExample)
IL (1) IL216201A (enExample)
MX (1) MX2011012108A (enExample)
NZ (2) NZ596470A (enExample)
PE (2) PE20161222A1 (enExample)
PH (1) PH12015501925A1 (enExample)
RU (1) RU2562245C2 (enExample)
SG (2) SG175929A1 (enExample)
UA (1) UA108986C2 (enExample)
WO (1) WO2010132110A1 (enExample)
ZA (1) ZA201108347B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
RU2553476C2 (ru) 2007-08-02 2015-06-20 Миллениум Фармасьютикалз, Инк. Способ синтеза ингибиторов е1-активирующего фермента
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
US20120115892A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
CN103889988B (zh) * 2011-08-24 2018-05-04 米伦纽姆医药公司 Nedd8-活化酶的抑制剂
JP6231988B2 (ja) 2011-11-03 2017-11-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
WO2013123169A1 (en) * 2012-02-17 2013-08-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
EP2879681A4 (en) * 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
CA2886783A1 (en) 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
US20160074404A1 (en) 2013-05-14 2016-03-17 Millennium Pharmaceutcals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
JP6603712B2 (ja) 2014-07-01 2019-11-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｓｕｍｏ活性化酵素の阻害薬として有用なヘテロアリール化合物
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
EP3684363A4 (en) * 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
JP2022521972A (ja) * 2019-02-26 2022-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッド アジュバントとして有用な化合物
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200900285A1 (ru) * 2006-08-08 2009-08-28 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
MXPA04005510A (es) 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
WO2003106477A1 (en) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
AU2005227997A1 (en) 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
PT1989206E (pt) * 2006-02-02 2012-10-15 Millennium Pharm Inc Inibidores da enzima de ativação e1
RU2553476C2 (ru) * 2007-08-02 2015-06-20 Миллениум Фармасьютикалз, Инк. Способ синтеза ингибиторов е1-активирующего фермента
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP6231988B2 (ja) 2011-11-03 2017-11-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
US20160074404A1 (en) 2013-05-14 2016-03-17 Millennium Pharmaceutcals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200900285A1 (ru) * 2006-08-08 2009-08-28 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOUCY T A; ET AL ,An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , NATURE, 09. 04.2009,Vol:458, Page(s):732 " 736 . WO2007092213 A2, 16 08.2007 & EA 200801784 A1 . *

Also Published As

Publication number Publication date
BRPI1012142A2 (pt) 2016-03-29
KR20120024715A (ko) 2012-03-14
PE20120907A1 (es) 2012-08-18
ZA201108347B (en) 2014-05-26
AU2010248151B2 (en) 2016-07-14
RU2011150826A (ru) 2013-06-20
US9187482B2 (en) 2015-11-17
WO2010132110A1 (en) 2010-11-18
NZ596470A (en) 2014-04-30
UA108986C2 (uk) 2015-07-10
AU2010248151A1 (en) 2011-12-01
JP2012526808A (ja) 2012-11-01
US20170000792A9 (en) 2017-01-05
SG175929A1 (en) 2011-12-29
EP3091020A2 (en) 2016-11-09
MX2011012108A (es) 2011-12-08
CA2761256C (en) 2021-01-05
IL216201A0 (en) 2012-01-31
US10016427B2 (en) 2018-07-10
EP3091020B1 (en) 2020-12-30
JP2015096547A (ja) 2015-05-21
JP2017105816A (ja) 2017-06-15
PE20161222A1 (es) 2016-12-01
KR20170102381A (ko) 2017-09-08
EP2430026A1 (en) 2012-03-21
CN102421780A (zh) 2012-04-18
CN104016987A (zh) 2014-09-03
US20110021544A1 (en) 2011-01-27
EP3091020A3 (en) 2017-01-11
US20160030432A1 (en) 2016-02-04
PH12015501925A1 (en) 2018-01-22
IL216201A (en) 2015-11-30
SG10201402148SA (en) 2014-07-30
NZ621128A (en) 2015-08-28
CA2761256A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
RU2562245C2 (ru) ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА
CA2532049C (en) Isethionate salt of a selective cdk4 inhibitor
US10017513B2 (en) Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate
JP6918824B2 (ja) ２−［（２Ｓ）−１−アザビシクロ［２．２．２］オクタ−２−イル］−６−（３−メチル−１Ｈ−ピラゾール−４−イル）チエノ［３，２−ｄ］ピリミジン−４（３Ｈ）−オン半水和物の結晶形
KR20140145157A (ko) 상피 성장 인자 수용체 키나제 억제제의 고체 형태
WO2021113661A1 (en) Amorphous and polymorphic form of a specific chk1 inhibitor
AU2011270890A1 (en) Polymorphs of OSI-906
ES2529105T3 (es) Compuestos, ciertas formas nuevas de los mismos, composiciones farmacéuticas de los mismos y métodos para su preparación y uso
US11124519B2 (en) Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
CN114728875A (zh) 金属盐及其用途
US20240368165A1 (en) Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
EP4169915A1 (en) Crystalline form of compound
HK1231052A1 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
AU2013204831A1 (en) Hydrochloride salt of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino] -7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
JP5701884B2 (ja) 三環性ピラゾロピリミジン誘導体の結晶
HK40077267A (en) Metal salts and uses thereof
US20140371249A1 (en) Crystal of a free tricyclic pyrazolopyrimidine derivative
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
HK1223101A1 (zh) Gdc-0032的多晶型物、其制备方法和药物用途
HK1223101B (zh) Gdc-0032的多晶型物、其制备方法和药物用途
HK1185080A (en) Free crystal of tricyclic pyrazolopyrimidine derivative

Legal Events

Date Code Title Description
HC9A Changing information about inventors
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180514